Figure 10 — A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis

Research Paper|Volume 9, Issue 10|pp. 2098–2116

A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis

Back to articleFigure 10(10 of 14)

100%

Figure 10.A short c-Myc-related mitochondrial signature predicts poor clinical outcome, in both ER(+) and ER(-) breast cancer patients. Note that this short 3-gene signature (HSPD1/COX5B/TIMM44) also effectively predicts tumor recurrence in larger populations of both ER(+) [N=3,082] and ER(-) [N=618] breast cancer patients. RFS, recurrence-free survival.